← FDA DRUG APPROVALS

FDA NDA · NDA050505

GARAMYCIN

Sponsor: SCHERING

APPLICATION
NDA050505
TYPE
NDA
ORIGINAL APPROVAL
1979-10-01
LATEST ACTION
1989-02-14
ROUTE
INTRATHECAL
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

GARAMYCIN · ReferenceDiscontinued
GENTAMICIN SULFATE EQ 2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INTRATHECAL

Approval history

1989-02-14Manufacturing (CMC) · Supplement 7 · standardAP
1987-03-20Manufacturing (CMC) · Supplement 6 · standardAP
1986-03-17Manufacturing (CMC) · Supplement 5 · standardAP
1983-10-17Labeling · Supplement 4 · standardAP
1983-05-17Labeling · Supplement 3 · standardAP
1982-10-29Labeling · Supplement 1 · standardAP
1980-10-21Labeling · Supplement 10 · standardAP
1980-03-18Labeling · Supplement 9 · standardAP
1979-10-01Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →